Healthcare provider profile · identity verified

Marta Onyskiv, M.D.

Family Practice · BOSTON, MA · NPI 1619081510

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	605	188
Lisinopril	Lisinopril	362	119
Omeprazole	Omeprazole	339	106
Levothyroxine Sodium	Levothyroxine Sodium	292	77
Amlodipine Besylate	Amlodipine Besylate	277	85
Metoprolol Succinate	Metoprolol Succinate	212	68
Gabapentin	Gabapentin	199	38
Hydrochlorothiazide	Hydrochlorothiazide	187	65
Simvastatin	Simvastatin	182	57
Metformin Hcl	Metformin Hcl	161	52
Losartan Potassium	Losartan Potassium	159	52
Eliquis	Apixaban	154	33
Metoprolol Tartrate	Metoprolol Tartrate	116	31
Allopurinol	Allopurinol	113	31
Atenolol	Atenolol	112	35
Citalopram Hbr	Citalopram Hydrobromide	109	32
Albuterol Sulfate Hfa	Albuterol Sulfate	104	33
Trazodone Hcl	Trazodone Hcl	97	23
Lorazepam	Lorazepam	95	33
Rosuvastatin Calcium	Rosuvastatin Calcium	92	30
Tamsulosin Hcl	Tamsulosin Hcl	92	27
Sertraline Hcl	Sertraline Hcl	88	23
Pantoprazole Sodium	Pantoprazole Sodium	86	35
Zolpidem Tartrate	Zolpidem Tartrate	83	11
Metformin Hcl Er	Metformin Hcl	76	27
Furosemide	Furosemide	75	25
Alendronate Sodium	Alendronate Sodium	69	22
Trulicity	Dulaglutide	64	12
Famotidine	Famotidine	57	15
Clonazepam	Clonazepam	50	suppressed
Potassium Chloride	Potassium Chloride	49	suppressed
Ezetimibe	Ezetimibe	48	11
Jardiance	Empagliflozin	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	47	15
Glipizide	Glipizide	47	11
Montelukast Sodium	Montelukast Sodium	42	15
Incruse Ellipta	Umeclidinium Bromide	41	suppressed
Levetiracetam	Levetiracetam	40	suppressed
Lovastatin	Lovastatin	40	16
Celecoxib	Celecoxib	39	11
Ibuprofen	Ibuprofen	39	15
Mirtazapine	Mirtazapine	39	16
Tramadol Hcl	Tramadol Hcl	39	16
Alprazolam	Alprazolam	38	suppressed
Meloxicam	Meloxicam	36	suppressed
Synthroid	Levothyroxine Sodium	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	35	11
Carvedilol	Carvedilol	34	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	33	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	32	12
Pregabalin	Pregabalin	32	suppressed
Clobetasol Propionate	Clobetasol Propionate	29	suppressed
Prednisone	Prednisone	28	17
Spironolactone	Spironolactone	28	suppressed
Topiramate	Topiramate	28	suppressed
Warfarin Sodium	Warfarin Sodium	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	12
Acyclovir	Acyclovir	25	suppressed
Finasteride	Finasteride	25	suppressed
Naproxen	Naproxen	25	11
Nystatin	Nystatin	25	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	24	suppressed
Gemfibrozil	Gemfibrozil	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	21	suppressed
Fenofibrate	Fenofibrate,micronized	21	suppressed
Glimepiride	Glimepiride	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	suppressed
Loperamide	Loperamide Hcl	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	20	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Verapamil Er	Verapamil Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Folic Acid	Folic Acid	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Midodrine Hcl	Midodrine Hcl	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Ozempic	Semaglutide	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Atrovent Hfa	Ipratropium Bromide	15	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Valsartan	Valsartan	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Bethanechol Chloride	Bethanechol Chloride	13	suppressed
Diazepam	Diazepam	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Klor-Con M20	Potassium Chloride	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Levoxyl	Levothyroxine Sodium	13	suppressed
Methimazole	Methimazole	13	suppressed
Novolog	Insulin Aspart	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Azithromycin	Azithromycin	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Eplerenone	Eplerenone	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Irbesartan	Irbesartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error